Clinical Trials Sponsored by ZIOPHARM

Total 1360 results

Renmin Hospital of Wuhan University
Ansun Biopharma, Inc.

Completed

DAS181 for Severe COVID-19: Compassionate Use

COVID-19

China
Seoul National University Hospital
HanAll BioPharma Co., Ltd.

Unknown

Changes in Body Composition With Patients Under Androgen Deprivation Therapy

Sarcopenia | Prostate Cancer

Korea, Republic of
UCB Biopharma S.P.R.L.
PRA Health Sciences

Completed

Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease (NEUPART)

Idiopathic Parkinson's Disease

Germany, France, Italy, Spain, United Kingdom
Arbutus Biopharma Corporation
United States Department of Defense

Terminated

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802

Ebola Virus Infection

United States
Ansun Biopharma, Inc.
National Institutes of Health (NIH)

Completed

Randomized, Double-blind, Placebo Controlled Phase II Study to Examine the Effects of DAS181 in Healthy Adult Subjects With Laboratory Confirmed Influenza

Influenza

United States
Green Cross Corporation
Quintiles, Inc.

Completed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of Orally Administered GCC4401C in Healthy Volunteers

Healthy Male

United States
Memorial Sloan Kettering Cancer Center
Ambrilia Biopharma, Inc.

Completed

Dose-Seeking Trial of PCK3145 in Asymptomatic, Castrate Metastatic Prostate Cancer Patients.

Prostate Cancer

United States
Lingli Dong
Shenzhen Pregene Biopharma Co., Ltd.

Recruiting

Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells

Lupus Nephritis | ANCA Associated Vasculitis

China
Lambda Therapeutic Research Ltd.
Intas Pharmaceutical Limited (Biopharma Division)

Recruiting

Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis

Osteoporosis, Postmenopausal

India
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.

Not yet recruiting

A Phase 1b Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

COVID-19
Zenith Epigenetics
Astellas Pharma Inc; Newsoara Biopharma Co., Ltd.

Recruiting

ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

United States, China
Adlai Nortye Biopharma Co., Ltd.
Merck Sharp & Dohme LLC

Active, not recruiting

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Cervical Cancer | Triple-negative Breast Cancer | NSCLC, Squamous or Non-Squamous | Urothelial Carcinoma of the Bladder | Microsatellite Stable (MSS) Colorectal Cancer (CRC)

United States, France
Jason J. Luke, MD
Array BioPharma

Active, not recruiting

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Melanoma | Renal Cell Carcinoma | Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma

United States
Weill Medical College of Cornell University
Oncolys BioPharma Inc

Completed

Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma

Esophagogastric Adenocarcinoma

United States
Qpex Biopharma, Inc.
Biomedical Advanced Research and Development Authority

Completed

Phase 1 Oral QPX7831 SAD and MAD in Healthy Adults

Bacterial Infections

Australia, United States
Qpex Biopharma, Inc.
Biomedical Advanced Research and Development Authority

Completed

P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV

Bacterial Infections

Australia, United States
Qpex Biopharma, Inc.
Biomedical Advanced Research and Development Authority

Completed

Phase 1 Study of Oral QPX2015 in Healthy Adult Subjects

Bacterial Infections

Australia
Connect Biopharma Australia Pty Ltd

Completed

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

Autoimmune Diseases

Australia, United States
Advagene Biopharma Co. Ltd.
Taipei Medical University; Clinipace Worldwide

Completed

Tolerability and Potential Efficacy of LTh(αΚ) in Subjects With Allergic Rhinitis

Allergic Rhinitis

Taiwan
National Taiwan University Hospital
Ono Pharmaceutical Co. Ltd; TTY Biopharm; ACT Genomics

Unknown

Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer
Estrella Biopharma, Inc.
Eureka Therapeutics Inc.

Not yet recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (STARLIGHT-1)

Lymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Walvax Biotechnology Co., Ltd.
Shanghai RNACure Biopharma Co., Ltd.

Not yet recruiting

A Phase 1a Trial to Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Chimera Vaccine Against COVID-19

COVID-19
Green Cross Corporation
Atlantic Research Group

Recruiting

Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency

Primary Immune Deficiency

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; Array BioPharma

Recruiting

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditions

United States
SmartNuclide Biopharma
The First Affiliated Hospital of Soochow University

Completed

A PET Imaging Agent to Assess the Level of Tumor Tissue-infiltrating CD8 + T Cells in Patients With Solid Tumors

Solid Tumor

China
Weill Medical College of Cornell University
Oncolys BioPharma Inc

Terminated

Phase 2 Study of OBP-301 (Telomelysin™) in Combination With Pembrolizumab and SBRT in Patients With HNSCC With Inoperable, Recurrent or Progressive Disease

Head and Neck Squamous Cell Carcinoma With Inoperable Recurrent or Progressive Disease

United States
Qpex Biopharma, Inc.
Biomedical Advanced Research and Development Authority

Completed

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers (QPX9003)

Bacterial Infections

United States
Qpex Biopharma, Inc.
Biomedical Advanced Research and Development Authority

Completed

Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects

Bacterial Infections

United States
Green Cross Corporation
Dream CIS, Inc.

Completed

A Study to Investigate the Safety, Tolerability, PK and PD of MG1113 in Healthy Subjects and Hemophilia Patients

Hemophilia

Korea, Republic of
OncoMed Pharmaceuticals, Inc.
Novotech (Australia) Pty Limited

Completed

A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer

Australia, New Zealand, Spain
OncoMed Pharmaceuticals, Inc.
Novotech (Australia) Pty Limited

Completed

A Study of Carboplatin and Pemetrexed Plus Demcizumab (OMP-21M18) in Subjects With Non-Squamous Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

Australia, New Zealand, Spain
Green Cross Corporation
Atlantic Research Group

Completed

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

Immunologic Deficiency Syndrome

United States, Canada
Green Cross Corporation
Atlantic Research Group

Unknown

Safety and Efficacy Extension Study of GreenGene™ F in Previously Treated Patients Diagnosed With Severe Hemophilia A

Hemophilia A

United States
Lytix Biopharma AS
Karolinska University Hospital; Oslo University Hospital

Completed

Dose-escalation Study of LTX-315 in Patients With a Transdermally Accessible Tumour

Cancer With Transdermal Accessible Tumour

Sweden, Norway
National Cheng-Kung University Hospital
National Health Research Institutes, Taiwan; TTY Biopharm

Completed

Add-on Dextromethorphan in Bipolar Disorders (DM)

Bipolar Disorder

Taiwan
Kiromic BioPharma Inc.
Statistics & Data Corporation; Stiris Research Inc

Recruiting

Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Stage 4 Metastatic NSCLC

Carcinoma, Non-Small-Cell Lung

United States
SmartNuclide Biopharma
The First Affiliated Hospital of Soochow University

Recruiting

[68Ga]Ga-NOTA-SNA002 (PD-L1 PET Tracer) for PET/CT in Patients With Solid Tumors

Solid Tumor | Positron-Emission Tomography(PET)

China
Principia Biopharma, a Sanofi Company
Massachusetts General Hospital

Active, not recruiting

Open Label Two-Arm Study to Evaluate Rilzabrutinib in IgG4-Related Disease Patients

Immunoglobulin G4 Related Disease

United States, Canada, France, Italy, Spain
Seoul National University Hospital
GC Biopharma Corp; Severance Hospital

Completed

IVIG/Rituximab vs Rituximab in Kidney Transplant With de Novo Donor-specific Antibodies

Renal Transplant

Korea, Republic of
Connect Biopharma Australia Pty Ltd

Completed

Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults

Healthy Adult Subjects

Australia
University of Utah
Bristol-Myers Squibb; Acrotech Biopharma Inc.

Withdrawn

Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation (BENEFIT)

Metastatic Adenocarcinoma
OncoMed Pharmaceuticals, Inc.
Novotech (Australia) Pty Limited

Completed

A Study of FOLFIRI Plus OMP-21M18 as 1st or 2nd-line Treatment in Subjects With Metastatic Colorectal Cancer

Colorectal Cancer

Australia, New Zealand
Peking Union Medical College Hospital
Zhitong Biopharma CO.,LTD

Unknown

A Study to Evaluate the Efficacy and Safety of Brain Polypeptide Solution in Mild Alzheimer's Disease

Alzheimer Disease
Green Cross Corporation
ICON Clinical Research

Terminated

Safety Study of MG1102 in Patients With Solid Tumors

Solid Tumors

Korea, Republic of
Green Cross Corporation
Atlantic Research Group

Unknown

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

Hemophilia A

United States, Canada, New Zealand, Poland, Russian Federation, Ukraine, United Kingdom
First Affiliated Hospital of Guangxi Medical University
Genmedicn Biopharma Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of the GMCN-508A Drug Product in Transfusion-dependent α-Thalassemia Participants

Transfusion-dependent α-Thalassemia

China
University of Michigan Rogel Cancer Center
Pfizer; Acrotech Biopharma Inc.

Recruiting

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Metastatic Breast Cancer | Metastatic Castration-resistant Prostate Cancer | Metastatic Ovarian Carcinoma

United States
Dr. Ferrer BioPharma
Hospital CEMESA Cortés, San Pedro Sula, Honduras

Completed

Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I (ACCROS-I)

Coronavirus Infections | COVID-19 | Coronavirus Disease 2019 | COVID-19 Pandemic | Symptoms and Signs

Honduras
State University of New York - Upstate Medical...
CTI BioPharma

Completed

A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

Carcinoma, Squamous Cell

United States
First Affiliated Hospital of Guangxi Medical University
Genmedicn Biopharma Ltd.

Recruiting

A Study Evaluating the Safety and Efficacy of LentiRed Drug Product in Transfusion-dependent β-Thalassemia [TDT]

Transfusion Dependent Beta-Thalassemia

China

Clinical Trials Sponsored by ZIOPHARM

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations